Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
05:30pm, Thursday, 07'th Aug 2025
ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Espe
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
12:45pm, Wednesday, 06'th Aug 2025
Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.
Esperion (ESPR) Q2 Revenue Jumps 12%
11:57pm, Tuesday, 05'th Aug 2025
Esperion (ESPR) Q2 Revenue Jumps 12%
Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript
10:10am, Tuesday, 05'th Aug 2025
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Alina Venezia - Corporate Participant Benjamin Halladay - Chief Financial Off
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
08:15am, Tuesday, 05'th Aug 2025
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.05 per share a year ago.
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update
06:00am, Tuesday, 05'th Aug 2025
– Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Qu
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
11:01am, Tuesday, 29'th Jul 2025
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Esperion to Report Second Quarter 2025 Financial Results on August 5
08:00am, Tuesday, 22'nd Jul 2025
ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025.
Esperion Appoints Craig Thompson to Board of Directors
08:06am, Tuesday, 01'st Jul 2025
Brings More Than Twenty Years of Biopharmaceutical Leadership Experience Brings More Than Twenty Years of Biopharmaceutical Leadership Experience
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?
07:03am, Saturday, 14'th Jun 2025
Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Mana
Why Is Esperion Therapeutics (ESPR) Up 28.6% Since Last Earnings Report?
12:37pm, Thursday, 05'th Jun 2025
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limite
Esperion to Participate in H.C. Wainwright's 3rd Annual BioConnect Investor Conference
08:00am, Friday, 09'th May 2025
ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Confer
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Thursday, 08'th May 2025
ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion
– Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Brin
